Zhan Xianquan, Wang Xiaowei, Cheng Tingting
Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, China; Hunan Engineering Laboratory for Structural Biology and Drug Design, Xiangya Hospital, Central South University, Changsha, China; State Local Joint Engineering Laboratory for Anticancer Drugs, Xiangya Hospital, Central South University, Changsha, China; The State Key Laboratory of Medical Genetics, Central South University, Changsha, China.
Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, China; Hunan Engineering Laboratory for Structural Biology and Drug Design, Xiangya Hospital, Central South University, Changsha, China; State Local Joint Engineering Laboratory for Anticancer Drugs, Xiangya Hospital, Central South University, Changsha, China.
Front Endocrinol (Lausanne). 2016 May 31;7:54. doi: 10.3389/fendo.2016.00054. eCollection 2016.
Pituitary adenoma (PA) is a common intracranial neoplasm that impacts on human health through interfering hypothalamus-pituitary-target organ axis systems. The development of proteomics gives great promises in the clarification of molecular mechanisms of a PA and discovery of effective biomarkers for prediction, prevention, early-stage diagnosis, and treatment for a PA. A great progress in the field of PA proteomics has been made in the past 10 years, including (i) the use of laser-capture microdissection, (ii) proteomics analyses of functional PAs (such as prolactinoma), invasive and non-invasive non-functional pituitary adenomas (NFPAs), protein post-translational modifications such as phosphorylation and tyrosine nitration, NFPA heterogeneity, and hormone isoforms, (iii) the use of protein antibody array, (iv) serum proteomics and peptidomics, (v) the integration of proteomics and other omics data, and (vi) the proposal of multi-parameter systematic strategy for a PA. This review will summarize these progresses of proteomics in PAs, point out the existing drawbacks, propose the future research directions, and address the clinical relevance of PA proteomics data, in order to achieve our long-term goal that is use of proteomics to clarify molecular mechanisms, construct molecular networks, and discover effective biomarkers.
垂体腺瘤（PA）是一种常见的颅内肿瘤，通过干扰下丘脑 - 垂体 - 靶器官轴系统影响人类健康。蛋白质组学的发展为阐明垂体腺瘤的分子机制以及发现用于垂体腺瘤预测、预防、早期诊断和治疗的有效生物标志物带来了巨大希望。在过去10年里，垂体腺瘤蛋白质组学领域取得了重大进展，包括：（i）使用激光捕获显微切割技术；（ii）对功能性垂体腺瘤（如催乳素瘤）、侵袭性和非侵袭性无功能性垂体腺瘤（NFPA）、蛋白质翻译后修饰（如磷酸化和酪氨酸硝化）、NFPA异质性以及激素异构体进行蛋白质组学分析；（iii）使用蛋白质抗体芯片；（iv）血清蛋白质组学和肽组学；（v）蛋白质组学与其他组学数据的整合；（vi）提出垂体腺瘤的多参数系统策略。本综述将总结蛋白质组学在垂体腺瘤方面的这些进展，指出存在的不足，提出未来的研究方向，并阐述垂体腺瘤蛋白质组学数据的临床相关性，以实现我们利用蛋白质组学阐明分子机制、构建分子网络并发现有效生物标志物的长期目标。
